Top TRT Brands for Optimal Hormone Health

Testosterone Replacement Therapy (TRT) has gained significant attention in recent years as more people seek effective solutions for age-related testosterone decline. Choosing the right brand for TRT is crucial, as it can significantly impact results and overall health outcomes. Some leading brands are known for their high-quality formulations, reliable delivery systems, and strong track record in clinical efficacy. In the following sections, we dive into the top brands in the TRT market, their unique offerings, and what makes them stand out.

Illustration of trt

Best brands of trt in 2025

TestoGen

TestoGen is a prominent brand in the testosterone supplement market, though it is not FDA-approved and lacks specific trials to support its efficacy. The supplement contains 11 natural ingredients, including D-aspartic acid, vitamin D3, and boron, which are claimed to boost testosterone levels and delay the conversion of testosterone to estrogen. A 2020 study found that boron supplementation can improve free testosterone levels after muscle strength training, which aligns with some of TestoGen's ingredient claims. However, only 24.8% of "T Booster" supplements, including those like TestoGen, have data to support their claims, according to a 2020 review. For detailed insights into their product offerings, visit the official TestoGen website.

Nugenix

Nugenix is a notable brand in the testosterone replacement therapy (TRT) and booster market, though it faces mixed reviews. Nugenix Total-T, one of its products, contains eight ingredients, with only three provided at clinically relevant doses. Despite this, Nugenix products are popular, with Total-T being the least expensive among its offerings, priced at $69.99 per bottle. However, the brand's online reputation is marred by low ratings on Trustpilot and the Better Business Bureau. The company offers a 14-day free trial and auto-ship program, which can be convenient but also raises concerns about automatic billing.

AndroGel

AndroGel, a leading product in the testosterone replacement therapy (TRT) market, is manufactured by AbbVie and has been a significant player since its approval. In 2012, AndroGel sales soared past $1.1 billion, although they declined subsequently due to FDA warnings and lawsuits. The product provides continuous transdermal delivery of testosterone, maintaining serum concentrations within the normal range for up to 180 days with proper application. Despite challenges, AndroGel remains a prominent brand, with its sales still substantial, such as $675 million in a recent year. Its efficacy in treating hypogonadism has been confirmed in clinical studies, with 87% of patients achieving normal serum testosterone levels. For further insights, please refer to the FDA's documentation on AndroGel.

Depo-Testosterone

Depo-Testosterone, a leading brand in testosterone replacement therapy (TRT), offers testosterone cypionate in various strengths, including 100 mg/mL and 200 mg/mL, administered intramuscularly into the gluteal muscle. The dosing ranges from 50 mg to 400 mg every 1 to 4 weeks, with guidelines from the American Urological Association (AUA) and the Endocrine Society recommending specific starting doses and intervals. This therapy is crucial for managing hypogonadism, with peak testosterone levels reaching supraphysiological ranges after injection before declining. The market for TRT, which includes Depo-Testosterone, is expected to grow significantly, with the global market size anticipated to exceed USD 2.93 billion by 2033, growing at a CAGR of 4.0% from 2023 to 2033. Depo-Testosterone is a reliable option, with its usage contributing to the 65% increase in testosterone supplement sales between 2009 and 2013. For more details on their products, visit the Depo-Testosterone product description page.

Testim

Testim, a leading brand in testosterone replacement therapy (TRT), offers a topical gel formulation that provides continuous transdermal delivery of testosterone for 24 hours, with approximately 10% of the applied dose absorbed into the systemic circulation. In clinical studies, 74% of hypogonadal men treated with Testim achieved average serum testosterone levels within the normal range by Day 90. Testim is available in 50 mg and 100 mg doses, with the 100 mg dose showing significant improvements in sexual function parameters. The product is indicated for adult males with conditions associated with a deficiency or absence of endogenous testosterone. It is crucial to measure serum testosterone concentrations to ensure proper dosing, typically 14 days after initiation of therapy. For more detailed information, visit the Testim drug webpage.

Fortesta

Fortesta is a highly effective testosterone replacement therapy (TRT) product, demonstrated by its ability to restore serum testosterone concentrations to physiologic levels in over 77% of patients within the normal range of 300 to 1140 ng/dL by day 90 of treatment. The product, available in a metered-dose pump, allows for dose adjustments between 10 mg and 70 mg of testosterone, ensuring personalized treatment. In clinical trials, such as the Phase 3 study FOR1C conducted in 2010, Fortesta showed a low incidence of adverse events and was well-tolerated, with most skin reactions being mild and moderate. The gel is applied once daily to the front and inner thighs, providing continuous transdermal delivery of testosterone for 24 hours. This makes Fortesta a suitable option for men with hypogonadism due to its efficacy and safety profile.

Axiron

Axiron, developed by Eli Lilly and Acrux, is a leading brand in testosterone replacement therapy (TRT), distinguished by its innovative underarm applicator. Approved by the FDA, Axiron has demonstrated efficacy in restoring testosterone levels to the normal range (300-1050 ng/dL) in 84% of men after 120 days of treatment. The product has shown strong market performance, with a significant share of new prescriptions and switches from other therapies like Androgel and Testim. Axiron's launch was marked by a milestone payment of $87 million to Acrux and has been a key contributor to the growing TRT market, which was valued at $1.2 billion in 2010. The product's success is further underscored by its protection under patents until 2026.

Androderm

Androderm is a highly efficacious testosterone replacement therapy (TRT) product, with up to 92% of patients achieving normal testosterone levels. It is available in two strengths, delivering approximately 2 mg or 4 mg of testosterone per day, and is designed for continuous 24-hour application to intact, non-scrotal skin. The product has been shown to normalize serum testosterone concentrations in a significant percentage of hypogonadal men, with average steady-state concentrations over 24 hours reaching around 613 ng/dL and 621 ng/dL for the 2.5 mg and 5 mg systems, respectively. Androderm is particularly notable for its effectiveness, with studies indicating that it can achieve normal morning serum testosterone concentrations during the first day of dosing. The product is manufactured by Watson Laboratories and distributed by Watson Pharma, highlighting its reliability and quality. For more information, you can explore the comprehensive details about Androderm on RxList.

Prime Male

Prime Male is a notable brand in the testosterone booster market, utilizing a formula backed by credible research to enhance testosterone levels. For instance, ingredients like ashwagandha have been shown to boost testosterone, and the product's 4,000IU dose of vitamin D is sufficient to influence testosterone levels in deficient men. However, it's important to note that Prime Male does not contain testosterone itself but rather promotes its production through ingredients that increase luteinizing hormone (LH) output. The product requires a regimen of four capsules daily, which can be cumbersome for some users. Despite this, it remains a popular choice for men seeking to increase their energy, gym performance, and sexual health. For more information, you can read a detailed Prime Male Review.

Nebido

Nebido, a brand of testosterone undecanoate, is highly regarded for its efficacy and safety in testosterone replacement therapy (TRT). It is administered via intramuscular injection, typically every 10-14 weeks, providing a steady and sustained release of testosterone. Studies have shown that Nebido significantly increases serum testosterone levels, with over 90% of patients and physicians assessing its efficacy as "good" or "very good". It also improves sexual desire, erectile function, and overall well-being, as evidenced by improvements in the International Index of Erectile Function (IIEF) and the Aging Males' Symptoms (AMS) Scale. Additionally, Nebido has been found to decrease cholesterol levels and is well-tolerated, with a low drop-out rate of around 9.7% in observational studies.